Corporate Office:
Solara Active Pharma Sciences Limited
TICEL Bio Park, 6th Floor,
Module No. 601, 602, 603, Phase II – CSIR Road,
Taramani, Chennai, Tamil Nadu – 600113.
Tel: +91 44 4344 6700
Fax: +91 44 47406190
E-mail: investors@solara.co.in
website: www.solara.co.in

Date: April 28, 2026

The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001	**The National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051
Scrip Code: 541540, 890202	**Scrip Code: SOLARA, SOLARAPP1**

Dear Sir/ Madam,

Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

We are enclosing herewith a press release issued by the Company titled hereunder, with respect to the EIR (Establishment Inspection Report) received from US FDA for the inspection completed and classified "Voluntary Action Indicated (VAI)" and concluded this inspection as "Closed".

"Solara is pleased to announce the successful closure of US FDA inspection of its Puducherry Facility with continued state of cGMP compliance."

Thanking you,

Yours Faithfully,
For Solara Active Pharma Sciences Limited

POOJA JAYA KUMAR
Digitally signed by POOJA JAYA KUMAR
Date: 2026.04.28 16:47:40 +05'30'

Pooja Jaya Kumar
Company Secretary and Compliance Officer
Membership No: A57415

PRESS RELEASE

WWW.SOLARA.CO.IN | BSE:541540 NSE: SOLARA BLOOMBERG: SOLARA: IN | SECTOR: PHARMACEUTICALS

Solara is pleased to announce the successful closure of US FDA inspection of its Puducherry Facility with continued state of cGMP compliance

Chennai, India – Apr 28, 2026: Solara Active Pharma Sciences Limited (Solara), a leading pure play Active Pharmaceutical Ingredient manufacturer is pleased to announce that its Ibuprofen manufacturing facility at Puducherry has successfully completed the Unannounced inspection carried out by the US Food and Drug Administration (US FDA) between 2nd to 6th Feb 2026. Based on the response submitted, within the stipulated timeline to the Agency, against the observations cited during the inspection, the Agency has issued an EIR (Establishment Inspection Report) on April 24, 2026 with inspection classification of the facility as "Voluntary Action Indicated (VAI)" and concluded this inspection as "Closed".

Solara continues to stay focused on maintaining the highest level of Quality Compliance across its manufacturing facilities.

Commenting on the Inspection Outcome, Sandeep Rao, MD & CEO said "We have successfully completed the FDA inspection at our Puducherry facility between 2nd to 6th Feb 2026. At the end of the inspection, four Form FDA 483 inspectional observations were issued by the investigator. The observations were procedural in nature. We had submitted our formal response to FDA well within the timeline set by the Agency and the Agency has issued an EIR and concluded that the inspection is closed. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy."

The successful outcome of the unannounced USFDA inspection at our facility exhibits our dedication to achieving Quality excellence consistently at all our manufacturing sites and our commitment to focus on world-class Quality and Regulatory Compliance, which remains a key pillar of our growth strategy.

The Puducherry site, an Ibuprofen manufacturing facility of Solara, is well equipped with world class infrastructure to cater to Ibuprofen & its derivatives requirements for the domestic and international markets. This site is inspected by various Regulatory Authorities including US FDA, EDQM, MHRA & HPRA.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, Solara offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services. Its API facilities are approved by various international regulatory agencies including the USFDA, EDQM, MFDS, WHO, HPRA, PMDA etc.

Investor / Analyst contact
Abhishek Singhal
✉ abhishek.singhal@solara.co.in
✆ +91 99877 66968

Statutory and corporate affairs
Pooja Jaya Kumar, Company Secretary
Raghavan V, AVP Accounts
✉ investors@solara.co.in